-
my country's first injection of new crown specific medicine has significant effect
Time of Update: 2021-12-01
The reporter learned from Beijing Ditan Hospital today that after 35 patients in Beijing used "sympathetic medication" that received China's self-developed neutralizing antibody drug DXP-604, their condition improved significantly in a short period of time .
-
The list of the 8th "Shulan Medicine Award" announced!
Time of Update: 2021-12-01
Member of the Standing Committee of the National People's Congress Zhou Tianhua, vice president of Zhejiang University, pointed out that a century of change is intertwined with the epidemic of the century, and health care has become an important integration point for coordinating epidemic prevention and control and promoting high-quality economic and social development .
-
More than 800,000 new crowns affect brain nerves in patients under 20 years old
Time of Update: 2021-12-01
According to a report from the European Network on the 22nd, the latest Italian research shows that the number of people under the age of 20 infected with the new crown has exceeded 800,000 .
-
ASTRA, a major scientific facility for translational medicine in China, ranks among the top ten in the world
Time of Update: 2021-12-01
The big data platform ASTRA for the construction of large scientific facilities of translational medicine in Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine ranked among the top ten and ranked eighth .
-
The biopharmaceutical market has great potential for development, and a large number of companies are deploying in this field
Time of Update: 2021-12-01
From the perspective of industry insiders, as one of the leading domestic insulin companies, Ganli Pharmaceutical's investment in Saifen Technology is a new exploration in deepening the layout of the biopharmaceutical industry chain .
-
National Health Commission: The current round of the epidemic across the country has entered the final stage
Time of Update: 2021-12-01
National Health Commission: The current round of the epidemic across the country has entered the final stage National Health Commission: The current round of the national epidemic h
-
Newly diagnosed 38 new crowns on the 21st, including 7 local cases
Time of Update: 2021-12-01
As of 24:00 on November 21, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 1051 confirmed cases (including 11 severe cases), a total of 92,818 cured and discharged cases, and a total of 4,636 deaths.
-
Deck Pharmaceuticals announced that it will hold its first R&D day on November 16 and 18, 2021
Time of Update: 2021-11-16
November 16th: Online meeting (English session) November 18: Offline meeting will be webcast simultaneously (Chinese session)Shanghai and Hong Kong October 25, 2021/PRNewswire/ - A leading biopharmaceutical company dedicated to the research, development and commercialization of innovative tumor therapies – Deqi Pharmaceutical Co.
-
TOP10 failed clinical studies in September 2021
Time of Update: 2021-11-16
A head-to-head phase III study of Margetuximab in the treatment of breast cancerOn September 7, MacroGenics announced that the head-to-head SOPHIA study (NCT02492711) of Margetuximab versus trastuzumab combined with chemotherapy in the treatment of HER2-positive metastatic breast cancer did not prove to have a statistically significant advantage in the final OS analysis .
-
Lybalvi launches in the U.S. to treat schizophrenia and bipolar I disorder
Time of Update: 2021-11-16
The approval is based on data from 27 clinical studies, including 18 studies evaluating Lybalvi, 9 studies evaluating samidorphan separately, and FDA's olanzapine treatment of biphasic An investigation into the safety and effectiveness of type I disorders and schizophrenia was found .
-
Many "problem" pharmacies in Beijing closed for rectification
Time of Update: 2021-11-16
Shijingshan night investigation and unannounced visit to closed problem pharmaciesThe Shijingshan District Market Supervision Bureau has also stepped up its inspections of pharmacies in its jurisdiction, and organized law enforcement personnel to conduct open and unannounced visits to the pharmacies' implementation of epidemic prevention and control through the linkage of science and research institutes .
-
The first drug to treat uveitis-related macular edema!
Time of Update: 2021-11-16
Xipere is designed to use the proprietary SCS Microinjector® technology developed by Clearside to treat macular edema associated with uveitis through suprachoroidal administration .
-
Many pharmacies who bought and sold pharmacist's certificates were chased for criminal responsibility
Time of Update: 2021-11-16
"According to the information in the indictment, since April 2020, the defendant Yang Moujia (manager of the store management department of a pharmaceutical chain company in Jiaxing City) has collected more than RMB 580,000 for the application of certificates from 68 personnel for the purpose of profit-making.
-
HRS9531 Injection, a subsidiary of Hengrui Pharmaceuticals, obtained the notification of drug clinical trial approval
Time of Update: 2021-11-16
HRS9531 injection is an innovative drug independently developed by the company, and its indication is type 2 diabetes .
-
Why is the poisonous "Cruise officinalis" in Yang Guo's body really a medicine?
Time of Update: 2021-11-16
Figure 3 Alkaloids in GelsemiumPharmacological studies have proved that Gelsemium alkaloids have the effects of analgesia, immune regulation and tumor growth inhibition, and they are clinically used to treat cancer pain, sciatica, smooth muscle colic and other pains, as well as eczema, furuncle carbuncle, and psoriasis.
-
Next year, submit a new indication application for the blockbuster IL-4/IL-13 inhibitor phase 3 clinical report again
Time of Update: 2021-11-16
Today, Regeneron and Sanofi announced that Dupixent, a blockbuster IL-4/IL-13 inhibitor, reached the dual primary endpoint in the second clinical trial for the treatment of eosinophilic esophagitis (EoE) .
-
Hengrui Cyclophosphamide Capsules intends to give priority to review while 2 new drugs are approved for clinical trials
Time of Update: 2021-11-16
Article source: Medical Rubik's Cube InfoAuthor: SunshineRecently, the CDE official website showed that Hengrui cyclophosphamide capsules are planned to be included in the priority review and are suitable for the treatment of lymphoma, leukemia, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, breast cancer and many other tumor types .
-
AbbVie's oral CGRP antagonist Qulipta receives FDA approval for preventive treatment of migraine
Time of Update: 2021-11-16
The results of the key phase 2b/3 trial of the drug showed that all three doses of Qulipta treatment group reached the primary efficacy endpoint of improvement from baseline in average migraine days during the 12-week treatment period, and the patient was compared with the baseline level of the placebo group.
-
Dongyang Sunshine's insulin glargine is about to be approved
Time of Update: 2021-11-16
cn/v5/home/)In the sixth round of centralized insulin procurement of the list announced in September, the products included are all second- and third-generation insulins, grouped by quick-acting, basic and premix .
-
Tianjing Biotech announces that the Phase 2 clinical trial of TJ107 and PD-1 antibody combination drug has been approved by NMPA to start
Time of Update: 2021-11-16
The company announced today that the Center for Drug Evaluation of the National Medical Products Administration of China has formally approved the initiation of the combination of efilinterleukin alpha (also known as TJ107/GX-I7/NT-I7) and PD-1 antibody in the treatment of advanced solid tumors (including three negative Breast cancer and head and neck cancer) phase 2 clinical trials .
